Dermapharm Holding SE (DE:DMP)
XETRA:DMP
Top Page
Dermapharm Holding SE
(XETRA:DMP)
Select Model
Select Model
Rating:64Neutral
Price Target:
€40.00
▼(-4.42% Downside)
Action:DowngradedDate:12/19/25
Dermapharm Holding SE earns an overall score of 64, driven primarily by stable financial performance with strong margins but hampered by revenue stagnation and high leverage. Bullish technical momentum provides a positive lift, while reasonable valuation with a solid dividend yield adds support. Financial challenges remain the key risk to monitor.
Positive Factors
Operational Efficiency
Strong operational efficiency with stable gross profit margins and a solid EBIT margin indicates effective cost management and profitability.
Negative Factors
Revenue Growth
Inconsistent revenue growth and recent declines suggest challenges in maintaining sales momentum, potentially impacting long-term growth.
Read all positive and negative factors
Positive Factors
Negative Factors
Operational Efficiency
Strong operational efficiency with stable gross profit margins and a solid EBIT margin indicates effective cost management and profitability.
Read all positive factors
Dermapharm Holding SE (DMP) vs. iShares MSCI Germany ETF (EWG)
Market Cap
€2.25B
Dividend Yield2.34%
Average Volume (3M)18.50K
Price to Earnings (P/E)10.6
Beta (1Y)0.56
Revenue Growth0.11%
EPS Growth28.09%
CountryDE
Employees3,610
SectorHealthcare
Sector Strength45
IndustryDrug Manufacturers - Specialty & Generic
Share Statistics
EPS (TTM)0.69
Shares Outstanding53,840,000
10 Day Avg. Volume17,993
30 Day Avg. Volume18,498
Financial Highlights & Ratios
PEG Ratio0.22
Price to Book (P/B)3.47
Price to Sales (P/S)1.77
P/FCF Ratio12.84
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
€34.00Price Target Upside-18.76% Downside
Rating ConsensusHold
Number of Analyst Covering1
EPS Forecast (FY)2.52
Revenue Forecast (FY)€1.23B
Dermapharm Holding SE Business Overview & Revenue Model
Company Description
Dermapharm Holding SE, together with its subsidiaries, engages in the off-patent branded pharmaceuticals business in Germany and internationally. It operates through three segments: Branded Pharmaceuticals and Other Healthcare Products, Parallel I...
How the Company Makes Money
Dermapharm generates revenue primarily through the sale of its pharmaceutical products, which includes both generic and specialty medications. The company's revenue model is driven by the production and distribution of its extensive product portfo...
Dermapharm Holding SE Financial Statement Overview
Summary
Income Statement
65
Positive
Balance Sheet
55
Neutral
Cash Flow
50
Neutral
| Breakdown | TTM | Dec 2024 | Dec 2023 | Dec 2022 | Mar 2022 | Mar 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 1.16B | 1.18B | 1.14B | 1.02B | 942.91M | 793.83M |
| Gross Profit | 683.97M | 767.07M | 719.16M | 660.83M | 620.69M | 463.48M |
| EBITDA | 311.71M | 320.91M | 265.55M | 329.81M | 358.10M | 183.81M |
| Net Income | 116.03M | 113.79M | 62.37M | 134.24M | 209.58M | 85.83M |
Balance Sheet | ||||||
| Total Assets | 2.12B | 2.08B | 2.16B | 1.41B | 1.41B | 1.22B |
| Cash, Cash Equivalents and Short-Term Investments | 146.58M | 121.71M | 159.54M | 161.36M | 172.06M | 121.66M |
| Total Debt | 1.01B | 979.61M | 1.08B | 516.45M | 580.30M | 606.80M |
| Total Liabilities | 1.47B | 1.47B | 1.62B | 880.34M | 907.13M | 899.81M |
| Stockholders Equity | 649.22M | 604.42M | 539.21M | 531.59M | 497.32M | 321.97M |
Cash Flow | ||||||
| Free Cash Flow | 144.16M | 163.14M | 177.88M | 249.52M | 189.16M | 90.30M |
| Operating Cash Flow | 186.28M | 201.38M | 219.42M | 288.53M | 250.37M | 131.10M |
| Investing Cash Flow | -46.22M | -29.61M | -415.43M | -99.01M | -129.35M | -105.91M |
| Financing Cash Flow | -110.07M | -209.17M | 204.54M | -199.77M | -80.98M | -14.09M |
Dermapharm Holding SE Technical Analysis
Neutral
41.85
Price Trends
39.37
Positive
38.24
Positive
35.84
Positive
Market Momentum
1.33
Positive
50.30
Neutral
50.08
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For DE:DMP, the sentiment is Neutral. The current price of 41.85 is below the 20-day moving average (MA) of 42.33, above the 50-day MA of 39.37, and above the 200-day MA of 35.84, indicating a neutral trend. The MACD of 1.33 indicates Positive momentum. The RSI at 50.30 is Neutral, neither overbought nor oversold. The STOCH value of 50.08 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Neutral sentiment for DE:DMP.
Dermapharm Holding SE Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
64 Neutral | €2.25B | 10.63 | 18.56% | 2.34% | 0.11% | 28.09% | |
58 Neutral | €49.09B | 20.44 | 9.02% | 1.82% | 1.47% | 9.64% | |
56 Neutral | €329.53M | 23.60 | 2.97% | ― | 9.27% | 65.65% | |
53 Neutral | €332.96M | -2.28 | -39.02% | ― | -14.84% | -338.52% | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% |
* Healthcare Sector Average
DE:DMP
Dermapharm Holding SE
41.85
6.64
18.85%
DE:B8FK
Biofrontera
2.57
0.11
4.47%
DE:MRK
Merck KGaA
112.90
2.49
2.26%
DE:ILM1
Medios AG
12.92
2.34
22.12%
DE:PHH2
PAUL HARTMANN AG
211.00
-15.57
-6.87%
DE:FYB
Formycon AG
18.84
-3.01
-13.78%
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.